PRTA Prothena Corporation plc

Biotech Analyst Ratings

Latest News

1. 05 May 2022 Prothena Reports First Quarter 2022 Financial Results and Business Highlights

   • Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 million
   • Advanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer's disease, into a Phase 1 clinical study and received FDA Fast Track designation
   • Multiple presentations at AD/PD 2022 highlighting depth of neurodegenerative portfolio targeting Alzheimer's and Parkinson's diseases
     

   DUBLIN, Ireland, May 05, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter 2022.

   "We…

   View Full Article
2. 28 April 2022 Prothena to Report First Quarter 2022 Financial Results on May 5th

   DUBLIN, Ireland, April 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2022 financial results on Thursday, May 5, 2022 after the close of the U.S. financial markets.
   

   Consistent with past practice, the Company will not be conducting a conference call in conjunction with this financial results release on May 5.

   About Prothena

   Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating…

   View Full Article
3. 26 April 2022 Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

   • PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer's disease

   DUBLIN, Ireland, April 26, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody therapy currently being investigated in a Phase 1 clinical study for the treatment of Alzheimer's disease. The FDA's Fast Track designation program is designed to expedite the development…

   View Full Article
4. 28 March 2022 Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer's Disease

   • Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer's disease

   DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust pipeline of novel investigational therapeutics built on protein dysregulation expertise, today announced that the U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for PRX012, a potential best-in-class anti-amyloid beta (Aβ) antibody in development for the treatment of Alzheimer's disease (AD). Prothena has initiated the Phase 1 single ascending dose (SAD) study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of PRX012…

   View Full Article
5. 21 March 2022 Prothena to Participate in Stifel 2022 Virtual CNS Days

   DUBLIN, Ireland, March 21, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that members of its senior management team will participate in a fireside chat at the Stifel 2022 Virtual CNS Days on Monday March 28, 2022 at 12:30 PM ET.
   

   A live webcast of the fireside chat can be accessed through the investor relations section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

   About Prothena

   Prothena Corporation plc is a…

   View Full Article